CL2019000045A1 - Derivados etinilo. - Google Patents

Derivados etinilo.

Info

Publication number
CL2019000045A1
CL2019000045A1 CL2019000045A CL2019000045A CL2019000045A1 CL 2019000045 A1 CL2019000045 A1 CL 2019000045A1 CL 2019000045 A CL2019000045 A CL 2019000045A CL 2019000045 A CL2019000045 A CL 2019000045A CL 2019000045 A1 CL2019000045 A1 CL 2019000045A1
Authority
CL
Chile
Prior art keywords
compounds
ethynyl derivatives
isometer
emesis
neuroprotection
Prior art date
Application number
CL2019000045A
Other languages
English (en)
Inventor
Georg Jaeschke
Antonio Ricci
Barbara Biemans
Fionn O`Hara
Daniel Rueher
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2019000045A1 publication Critical patent/CL2019000045A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULAS IA Y IB, O A UNA SAL O SAL DE ADICIÓN DE ÁCIDO FARMACÉUTICAMENTE ACEPTABLE, A UNA MEZCLA RACÉMICA O A SU ENANTIÓMERO Y/O ISÓMERO ÓPTICO Y/O ESTEREOISÓMERO CORRESPONDIENTE DE LOS MISMOS. LOS COMPUESTOS PUEDEN UTILIZARSE EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, LA ANSIEDAD, LA EMESIS, EL TRASTORNO OBSESIVO-COMPULSIVO, EL AUTISMO, LA NEUROPROTECCIÓN, EL CÁNCER, LA DEPRESIÓN Y LA DIABETES DE TIPO 2.
CL2019000045A 2016-07-18 2019-01-07 Derivados etinilo. CL2019000045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16179837 2016-07-18

Publications (1)

Publication Number Publication Date
CL2019000045A1 true CL2019000045A1 (es) 2019-06-07

Family

ID=56418435

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000045A CL2019000045A1 (es) 2016-07-18 2019-01-07 Derivados etinilo.

Country Status (31)

Country Link
US (3) US20190144458A1 (es)
EP (1) EP3484889B1 (es)
JP (1) JP6936305B2 (es)
KR (1) KR20190026805A (es)
CN (1) CN109476671B (es)
AR (1) AR109075A1 (es)
AU (1) AU2017299083B2 (es)
BR (1) BR112019000314A2 (es)
CA (1) CA3030788A1 (es)
CL (1) CL2019000045A1 (es)
CO (1) CO2018013824A2 (es)
CR (1) CR20190014A (es)
DK (1) DK3484889T3 (es)
ES (1) ES2826389T3 (es)
HR (1) HRP20201615T1 (es)
HU (1) HUE051006T2 (es)
IL (1) IL263884A (es)
LT (1) LT3484889T (es)
MA (1) MA45665B1 (es)
MX (1) MX376249B (es)
PE (1) PE20190382A1 (es)
PH (1) PH12019500119A1 (es)
PL (1) PL3484889T3 (es)
PT (1) PT3484889T (es)
RS (1) RS60908B1 (es)
RU (1) RU2745068C2 (es)
SG (1) SG11201811829QA (es)
SI (1) SI3484889T1 (es)
TW (1) TWI729169B (es)
WO (1) WO2018015235A1 (es)
ZA (1) ZA201900113B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120463C2 (uk) 2015-07-15 2019-12-10 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як модулятори метаботропного рецептора глутамату
CN110183456A (zh) * 2019-07-11 2019-08-30 河南师范大学 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法
US11515154B2 (en) * 2020-10-27 2022-11-29 Applied Materials, Inc. Selective deposition of a passivation film

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2508581A1 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
PL1891075T3 (pl) 2005-05-24 2011-12-30 Merck Serono Sa Spiropochodne tricykliczne jako modulatory CRTH2
WO2008027466A1 (en) 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
RU2012114770A (ru) 2009-09-04 2013-10-10 Вандербилт Юниверсити АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
HRP20150555T1 (hr) 2011-04-26 2015-07-03 F. Hoffmann - La Roche Ag Derivati etinila kao pozitivni alosterijski modulatori za mglur5
EP2702050B1 (en) 2011-04-26 2016-05-18 F.Hoffmann-La Roche Ag Pyrazolidin-3-one derivatives
WO2012162635A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
AU2012278976B2 (en) * 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
UA110995C2 (uk) 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
AU2013292142B2 (en) 2012-07-17 2017-03-09 F. Hoffmann-La Roche Ag Arylethynyl derivatives
MY171517A (en) 2012-10-18 2019-10-16 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
CN104718191B (zh) 2012-10-18 2016-06-29 霍夫曼-拉罗奇有限公司 作为mglur5受体活性调节剂的乙炔基衍生物
WO2014124560A1 (en) 2013-02-18 2014-08-21 Hua Medicine (Shanghai) Ltd. Mglur regulators
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
EA029352B1 (ru) 2013-09-25 2018-03-30 Ф. Хоффманн-Ля Рош Аг Производные этинила
TWI649310B (zh) 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
HUE041392T2 (hu) 2014-02-25 2019-05-28 Hoffmann La Roche Etinil származékok
CN107207481B (zh) 2015-03-19 2020-03-03 豪夫迈·罗氏有限公司 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物
UA120463C2 (uk) * 2015-07-15 2019-12-10 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як модулятори метаботропного рецептора глутамату
US10391998B2 (en) 2016-11-16 2019-08-27 Ford Global Technologies, Llc Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness

Also Published As

Publication number Publication date
CO2018013824A2 (es) 2018-12-28
PE20190382A1 (es) 2019-03-08
PL3484889T3 (pl) 2020-12-28
US11242349B2 (en) 2022-02-08
ES2826389T3 (es) 2021-05-18
MA45665B1 (fr) 2020-11-30
RU2745068C2 (ru) 2021-03-18
SI3484889T1 (sl) 2020-11-30
SG11201811829QA (en) 2019-02-27
JP6936305B2 (ja) 2021-09-15
JP2019521158A (ja) 2019-07-25
US20200255440A1 (en) 2020-08-13
LT3484889T (lt) 2020-11-10
TW201805287A (zh) 2018-02-16
RU2019102757A3 (es) 2020-08-18
TWI729169B (zh) 2021-06-01
HUE051006T2 (hu) 2021-01-28
ZA201900113B (en) 2019-09-25
BR112019000314A2 (pt) 2019-04-16
US20220127275A1 (en) 2022-04-28
EP3484889A1 (en) 2019-05-22
CN109476671A (zh) 2019-03-15
HRP20201615T1 (hr) 2020-12-11
RS60908B1 (sr) 2020-11-30
CA3030788A1 (en) 2018-01-25
MX376249B (es) 2025-03-07
CN109476671B (zh) 2021-09-24
US12145940B2 (en) 2024-11-19
PH12019500119A1 (en) 2019-12-11
RU2019102757A (ru) 2020-08-18
AU2017299083B2 (en) 2021-06-24
AU2017299083A1 (en) 2019-01-24
PT3484889T (pt) 2020-10-15
DK3484889T3 (da) 2020-10-26
EP3484889B1 (en) 2020-08-19
KR20190026805A (ko) 2019-03-13
US20190144458A1 (en) 2019-05-16
MX2019000442A (es) 2019-06-20
IL263884A (en) 2019-01-31
AR109075A1 (es) 2018-10-24
WO2018015235A1 (en) 2018-01-25
CR20190014A (es) 2019-03-04

Similar Documents

Publication Publication Date Title
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
CL2018000036A1 (es) Derivados etinilo
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
MD20160109A2 (ro) Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
CL2013002424A1 (es) Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras.
AR099047A1 (es) Derivados etinilo
EA201790315A1 (ru) Модуляторы x-рецепторов печени
CL2019000045A1 (es) Derivados etinilo.
CL2016002064A1 (es) Derivados de etinilo.
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
AR104863A1 (es) Derivados imidazol
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
AR103952A1 (es) Derivados de pirimidina-diona
UA117780C2 (uk) Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
EA201792502A1 (ru) Кабазитаксел и его применение для лечения рака
CN302103642S (zh) 柜子
IN2013MU03838A (es)
CN302120534S (zh) 瓶
CN302239733S (zh) 输液瓶（50ml5%葡萄糖注射液）